Sonnet Biotherapeutics Holdings Inc (SONN)

$9.64 +4.47 (86.46%)
Market Cap 16.37M
Revenue (ttm) 20,000.00
Net Income (ttm) -7.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37,200.00%
Debt to Equity Ratio 0.00
Volume 44,593,301
Avg Vol 4,379,458
Day's Range N/A - N/A
Shares Out 3.17M
Stochastic %K 47%
Beta 0.98
Analysts Strong Sell
Price Target $20.00

Company Profile

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cance...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 375 2227
Address:
100 Overlook Center, Suite 102, Princeton, United States
hitlist0
hitlist0 Jul. 15 at 5:27 AM
$SONN what a gift for those who bought this last week
1 · Reply
Lawnchair45
Lawnchair45 Jul. 15 at 4:58 AM
$SONN watch the timely updates roll in now the previous Barclay’s CEO and Boston’s former fed chair are going to be on the board. More than likely a major shift will happen as they want all the hype they can get around their newly minted listing. Don’t get too excited because in no time the tech will be worth billions but all that value will be theirs. What’s your read @Pennystockmadness
0 · Reply
joe77w
joe77w Jul. 15 at 4:40 AM
$SONN pr said It Will change
1 · Reply
Jackie_Treehorn
Jackie_Treehorn Jul. 15 at 4:37 AM
$SONN will the ticker change when the deal actually executes?
0 · Reply
Kingjaff
Kingjaff Jul. 15 at 4:09 AM
$SONN Over night
0 · Reply
MadMaverick
MadMaverick Jul. 15 at 3:35 AM
🔥Watchlist Recap for 07/14/2025🔥 $DARE $SONN $YHC $SQFT
1 · Reply
24cmKarMadhfromPrishtina
24cmKarMadhfromPrishtina Jul. 15 at 3:24 AM
$SONN 🚀🚀
0 · Reply
GreenResearchers
GreenResearchers Jul. 15 at 3:23 AM
$SONN $PLTR $SONN $INKT WATCH TICKER - AQMS Watch ticker AQMS 28% short interest micro float ready for a 300% run AQMS isn’t hype it’s real IP in a trillion dollar space. They just secured a foundational patent for lithium battery recycling. That means licensing, scaling, and moat protection as battery demand explodes. Trading under the radar now but not for long.
0 · Reply
ALV_pinchytrader
ALV_pinchytrader Jul. 15 at 2:59 AM
$SONN $CLIK Loaded properly and holding With today’s two big news it should run huge Hong Kong, July 14, 2025 : Click Holdings Limited (CLIK) Secures Landmark HK$21.6 Million Government Contract with Major Hong Kong Postal Service Provider Hong Kong, July 14, 2025 : Click Holdings Limited (CLIK) Pioneers Cryptocurrency Revolution in Senior Care: Exploring $100M Treasury in Bitcoin and Solana to Drive Innovation in the Booming Silver Economy
0 · Reply
Dumont77
Dumont77 Jul. 15 at 2:53 AM
$SONN was up 200% this morning..I sold half of my position. Great pick. I had it for months. Need to do research to see how I picked this stock and use the system that picked it more often. #trading #stocks #market
1 · Reply
Latest News on SONN
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 11:30 AM EDT - 14 hours ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Jul 14, 2025, 6:00 AM EDT - 19 hours ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

May 1, 2025, 9:00 AM EDT - 2 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet Releases Virtual Investor "What This Means" Segment

Apr 16, 2025, 9:10 AM EDT - 3 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 4, 2025, 9:00 AM EDT - 3 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 4:15 PM EDT - 3 months ago

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Apr 1, 2025, 7:30 AM EDT - 3 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 26, 2025, 9:05 AM EDT - 3 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 19, 2025, 8:50 AM EDT - 4 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 4 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 26, 2025, 9:00 AM EST - 4 months ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 19, 2025, 8:35 AM EST - 5 months ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 18, 2025, 9:15 AM EST - 5 months ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:30 AM EST - 5 months ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Feb 13, 2025, 8:00 AM EST - 5 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 28, 2025, 9:05 AM EST - 5 months ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 8:35 AM EST - 6 months ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Jan 21, 2025, 9:05 AM EST - 6 months ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 23, 2024, 9:20 AM EST - 7 months ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 17, 2024, 8:50 AM EST - 7 months ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 3:42 PM EST - 7 months ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 9, 2024, 8:45 AM EST - 7 months ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Dec 4, 2024, 9:20 AM EST - 7 months ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 12, 2024, 9:15 AM EST - 8 months ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 1:20 PM EST - 8 months ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Nov 6, 2024, 8:30 AM EST - 8 months ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 17, 2024, 8:45 AM EDT - 9 months ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 9, 2024, 8:45 AM EDT - 9 months ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Oct 4, 2024, 8:30 AM EDT - 10 months ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 30, 2024, 9:00 AM EDT - 10 months ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 25, 2024, 8:30 AM EDT - 10 months ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 18, 2024, 8:30 AM EDT - 10 months ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 4, 2024, 9:15 AM EDT - 11 months ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 19, 2024, 8:45 AM EDT - 11 months ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:35 AM EDT - 11 months ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

May 6, 2024, 7:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Feb 29, 2024, 4:05 PM EST - 1 year ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Feb 14, 2024, 7:30 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Dec 21, 2023, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Dec 14, 2023, 4:15 PM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Oct 31, 2023, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

Oct 25, 2023, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

hitlist0
hitlist0 Jul. 15 at 5:27 AM
$SONN what a gift for those who bought this last week
1 · Reply
Lawnchair45
Lawnchair45 Jul. 15 at 4:58 AM
$SONN watch the timely updates roll in now the previous Barclay’s CEO and Boston’s former fed chair are going to be on the board. More than likely a major shift will happen as they want all the hype they can get around their newly minted listing. Don’t get too excited because in no time the tech will be worth billions but all that value will be theirs. What’s your read @Pennystockmadness
0 · Reply
joe77w
joe77w Jul. 15 at 4:40 AM
$SONN pr said It Will change
1 · Reply
Jackie_Treehorn
Jackie_Treehorn Jul. 15 at 4:37 AM
$SONN will the ticker change when the deal actually executes?
0 · Reply
Kingjaff
Kingjaff Jul. 15 at 4:09 AM
$SONN Over night
0 · Reply
MadMaverick
MadMaverick Jul. 15 at 3:35 AM
🔥Watchlist Recap for 07/14/2025🔥 $DARE $SONN $YHC $SQFT
1 · Reply
24cmKarMadhfromPrishtina
24cmKarMadhfromPrishtina Jul. 15 at 3:24 AM
$SONN 🚀🚀
0 · Reply
GreenResearchers
GreenResearchers Jul. 15 at 3:23 AM
$SONN $PLTR $SONN $INKT WATCH TICKER - AQMS Watch ticker AQMS 28% short interest micro float ready for a 300% run AQMS isn’t hype it’s real IP in a trillion dollar space. They just secured a foundational patent for lithium battery recycling. That means licensing, scaling, and moat protection as battery demand explodes. Trading under the radar now but not for long.
0 · Reply
ALV_pinchytrader
ALV_pinchytrader Jul. 15 at 2:59 AM
$SONN $CLIK Loaded properly and holding With today’s two big news it should run huge Hong Kong, July 14, 2025 : Click Holdings Limited (CLIK) Secures Landmark HK$21.6 Million Government Contract with Major Hong Kong Postal Service Provider Hong Kong, July 14, 2025 : Click Holdings Limited (CLIK) Pioneers Cryptocurrency Revolution in Senior Care: Exploring $100M Treasury in Bitcoin and Solana to Drive Innovation in the Booming Silver Economy
0 · Reply
Dumont77
Dumont77 Jul. 15 at 2:53 AM
$SONN was up 200% this morning..I sold half of my position. Great pick. I had it for months. Need to do research to see how I picked this stock and use the system that picked it more often. #trading #stocks #market
1 · Reply
mikesterz7
mikesterz7 Jul. 15 at 2:41 AM
$SONN LIST LOSSES HERE:
1 · Reply
Stock_Catcher
Stock_Catcher Jul. 15 at 2:39 AM
Money Tuesday Watchlist Pt. 2 $CAN $SONN $MARA $IXHL $NIO Let's have a nice day tomorrow
0 · Reply
Jestofunk
Jestofunk Jul. 15 at 2:33 AM
$SONN Investors stop listening to pumpers and becoming bag holders!
1 · Reply
jesusnavarrete
jesusnavarrete Jul. 15 at 1:46 AM
$SONN https://youtu.be/WJMIwzOiQcc
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 15 at 1:42 AM
$BLMZ $4.30 coming. new youtube : VTUBE coming. boom like $SQFT and $SONN
1 · Reply
davis8uni
davis8uni Jul. 15 at 1:34 AM
$SONN Appreciate the guidance! He is really good on this. Recommended! https://www.youtube.com/watch?v=TFYSdhhpR3A
0 · Reply
habesha_kingtchalla
habesha_kingtchalla Jul. 15 at 1:29 AM
$SDST $IBG $SQFT $SONN $GRO
1 · Reply
Stock_Catcher
Stock_Catcher Jul. 15 at 1:20 AM
Made a New Video Just Now on $SONN $DARE $GNLN $VSEE $TMC https://www.youtube.com/watch?v=wLXsbz0FUIY&t=3s
1 · Reply
Jestofunk
Jestofunk Jul. 15 at 12:56 AM
$SONN some cheeky bastard as put a $9 options trade in 😅
1 · Reply
Jestofunk
Jestofunk Jul. 15 at 12:53 AM
$SONN keep holding! Yesterday was just a temper too get the paperhands out
1 · Reply
Godwins26
Godwins26 Jul. 15 at 12:42 AM
Strong Watchlist for tomorrow 🤑 $SDST that $1 is in your reach 😊 $IBG Good job😀 $SQFT keep it up 😁 $SONN get back to 100% 🙂 $GRO strong finish 💪
1 · Reply
dbr_island
dbr_island Jul. 15 at 12:40 AM
TOLD YOU MONDAY WAS MADNESS 🤑 If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd Been doing this for over 20 years so I understand market behavior Now I may not get it right every time all the time But you have seen the results I have changed my life Now my focus is YOU 🫵 I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again I wish each one of you reading this a successful new year, and beyond ❤️ $SQFT $DARE $SDST $TROO $SONN see you all tomorrow!
1 · Reply